U.S. markets closed
  • S&P Futures

    3,807.00
    -9.75 (-0.26%)
     
  • Dow Futures

    31,195.00
    -41.00 (-0.13%)
     
  • Nasdaq Futures

    12,628.25
    -53.50 (-0.42%)
     
  • Russell 2000 Futures

    2,195.60
    -10.20 (-0.46%)
     
  • Crude Oil

    61.32
    +0.04 (+0.07%)
     
  • Gold

    1,712.10
    -3.70 (-0.22%)
     
  • Silver

    26.23
    -0.16 (-0.61%)
     
  • EUR/USD

    1.2051
    -0.0016 (-0.13%)
     
  • 10-Yr Bond

    1.4700
    +0.0550 (+3.89%)
     
  • Vix

    26.67
    +2.57 (+10.66%)
     
  • GBP/USD

    1.3930
    -0.0023 (-0.16%)
     
  • USD/JPY

    107.0540
    +0.0520 (+0.05%)
     
  • BTC-USD

    51,385.31
    +2,774.68 (+5.71%)
     
  • CMC Crypto 200

    1,026.97
    +38.87 (+3.93%)
     
  • FTSE 100

    6,675.47
    +61.72 (+0.93%)
     
  • Nikkei 225

    29,121.68
    -437.42 (-1.48%)
     

What You Need To Know About Taysha Gene Therapies, Inc.'s (NASDAQ:TSHA) Investor Composition

  • Oops!
    Something went wrong.
    Please try again later.
Simply Wall St
·4 min read
  • Oops!
    Something went wrong.
    Please try again later.

The big shareholder groups in Taysha Gene Therapies, Inc. (NASDAQ:TSHA) have power over the company. Institutions often own shares in more established companies, while it's not unusual to see insiders own a fair bit of smaller companies. I generally like to see some degree of insider ownership, even if only a little. As Nassim Nicholas Taleb said, 'Don’t tell me what you think, tell me what you have in your portfolio.

With a market capitalization of US$1.1b, Taysha Gene Therapies is a decent size, so it is probably on the radar of institutional investors. Our analysis of the ownership of the company, below, shows that institutions are noticeable on the share registry. Let's take a closer look to see what the different types of shareholders can tell us about Taysha Gene Therapies.

Check out our latest analysis for Taysha Gene Therapies

ownership-breakdown
ownership-breakdown

What Does The Institutional Ownership Tell Us About Taysha Gene Therapies?

Institutions typically measure themselves against a benchmark when reporting to their own investors, so they often become more enthusiastic about a stock once it's included in a major index. We would expect most companies to have some institutions on the register, especially if they are growing.

As you can see, institutional investors have a fair amount of stake in Taysha Gene Therapies. This suggests some credibility amongst professional investors. But we can't rely on that fact alone since institutions make bad investments sometimes, just like everyone does. When multiple institutions own a stock, there's always a risk that they are in a 'crowded trade'. When such a trade goes wrong, multiple parties may compete to sell stock fast. This risk is higher in a company without a history of growth. You can see Taysha Gene Therapies' historic earnings and revenue below, but keep in mind there's always more to the story.

earnings-and-revenue-growth
earnings-and-revenue-growth

We note that hedge funds don't have a meaningful investment in Taysha Gene Therapies. With a 25% stake, CEO R. Session is the largest shareholder. For context, the second largest shareholder holds about 14% of the shares outstanding, followed by an ownership of 11% by the third-largest shareholder.

After doing some more digging, we found that the top 3 shareholders collectively control more than half of the company's shares, implying that they have considerable power to influence the company's decisions.

Researching institutional ownership is a good way to gauge and filter a stock's expected performance. The same can be achieved by studying analyst sentiments. There are a reasonable number of analysts covering the stock, so it might be useful to find out their aggregate view on the future.

Insider Ownership Of Taysha Gene Therapies

While the precise definition of an insider can be subjective, almost everyone considers board members to be insiders. Management ultimately answers to the board. However, it is not uncommon for managers to be executive board members, especially if they are a founder or the CEO.

Insider ownership is positive when it signals leadership are thinking like the true owners of the company. However, high insider ownership can also give immense power to a small group within the company. This can be negative in some circumstances.

It seems insiders own a significant proportion of Taysha Gene Therapies, Inc.. It has a market capitalization of just US$1.1b, and insiders have US$415m worth of shares in their own names. That's quite significant. Most would say this shows a good degree of alignment with shareholders, especially in a company of this size. You can click here to see if those insiders have been buying or selling.

General Public Ownership

With a 16% ownership, the general public have some degree of sway over Taysha Gene Therapies. While this size of ownership may not be enough to sway a policy decision in their favour, they can still make a collective impact on company policies.

Next Steps:

While it is well worth considering the different groups that own a company, there are other factors that are even more important. Be aware that Taysha Gene Therapies is showing 3 warning signs in our investment analysis , and 1 of those is significant...

If you are like me, you may want to think about whether this company will grow or shrink. Luckily, you can check this free report showing analyst forecasts for its future.

NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.